Gastric Cancer
Conditions
Keywords
Gastric cancer, biomarker, chemotherapy, precise medicine
Brief summary
To conduct a retrospective study to prove a hypothesis of adjuvant chemotherapy provides survival benefit for patients of CTX-benefit group in gastric cancer of pT1N1, especially in high-risk group. This study is a pilot study and the result will be used as a reference for the upcoming prospective randomized controlled trial for same issue including estimating sample size. Two high-volume hospitals (Yonsei University Severance Hospital and Samsung Hospital) will participant this pilot study. FFPE sample blocks and clinical information pertaining to the patients who satisfied with selection criteria will be collected from two institutions. The primary end point of this study is disease-free survival (DFS) that is defined as the time from surgery to death or gastric cancer recurrence whichever occurred first; and overall survival (OS) that is defined as time from surgery to death by any causes. Clinical information such as age, sex, histology, Lauren classification, depth of invasion, number of retrieved and metastatic lymph nodes, sizes of tumor, location of tumor, gross type, lympho-vascular invasion, received chemotherapy or not will be centralized. One or 2 of 3mm core of tumor will be punched from FFPE and it will be delivered through Eppendorf tube to laboratory (Novomics Co. Ltd., Seoul, Korea). RNA will be extracted from the tissue and the pattern of RNA expression will be evaluated and each sample will be categorized into three risk group (high, intermediate, low risk group) and two predictive group (CTX-benefit and no-benefit group) by GMP-grade nProfiler 1TM Stomach Cancer Assay Kit (Novomics Co. Ltd., Seoul, Korea). Both clinical information and classification will be delivered to independent statisticians who are responsible to conduct statistical analyses.
Interventions
None listed
Sponsors
Yonsei University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Pathologically confirmed gastric adenocarcinoma 2. Patients who received R0 resection with curative intent surgery 3. pT1 (mucosa/submucosa) N1(one or two metastatic lymph nodes) M0 4. patients received surgery with lymph node dissection of D1 + or more 5. number of retrieved lymph nodes \>15 6. Formalin-Fixed Paraffin-Embedded cancer tissues are available 7. Adults over 19 years
Exclusion criteria
1. Patients received pre-operative chemotherapy or radiotherapy 2. Cancer in remnant stomach (history of gastrectomy) 3. in hospital mortality or died within 30 days after surgery 4. FFPE is not available
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease free survival | average 5 years to detect recurrence of tumor | Disease free survival which is defined as the time from surgery to death or gastric cancer recurrence whichever occurred first, and overall survival that is defined as time from surgery to death by any causes |
| overall survival | average of follow up duration will be 60 months | overall survival that is defined as time from surgery to death by any causes. Survival difference between surgery only vs. surgery plus adjuvant treatment (chemotherapy or chemo-radiotherapy) will be analyzed according to subgroup (CTX-benefit and no-benefit group in overall and high-risk group) |
Countries
South Korea
Outcome results
None listed